NCT02125474View on ClinicalTrials.gov

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

NACompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2019

Study Completion Date

October 1, 2019

Conditions
Neuroendocrine Tumors
Interventions
RADIATION

[177Lu] DOTA-TATE

We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.

Trial Locations (1)

00000

Instituto Nacional de Cancerología, Bogota

All Listed Sponsors
lead

Instituto Nacional de Cancerologia, Columbia

OTHER_GOV

NCT02125474 - Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate | Biotech Hunter | Biotech Hunter